Novartis hits the daily limit for four consecutive days; company issues risk warning

MetaMuskRat · 2026-03-27T19:08:24+00:00

Minoan hit the daily limit again on the 27th, achieving four consecutive limit-ups, with the stock price at 39.18 yuan. The company announced that its production and operations are normal, with no significant changes. Attention has been drawn to market discussions about its research data and clinical trials, and investors are reminded to view the uncertainties related to the product launch rationally.

MetaMuskRat

2026-03-27 19:08:24

Abstract generation in progress

Minohua (603538) hit the upper limit again during trading on the 27th, achieving a four-day limit-up streak. As of the time of writing, the stock is reported at 39.18 yuan/share, with more than 46,000 orders on the limit-up board.

The company announced on the evening of the 26th that, after self-examination, the company’s production and operational situation is normal, and there have been no significant changes in the internal and external operating environment. The main business has not undergone significant changes, and there is no other significant information that should be disclosed but has not been disclosed. There are no significant matters affecting the abnormal fluctuations in the company’s stock trading price.

The company has noted discussions in the market and among some channels regarding its related research data, clinical trial progress, and future development plans. JH389 is currently in the safety trial phase in Europe and has not yet submitted trial data to the relevant regulatory authorities. The progress of this product’s trials, data submission, and final approval for market launch will still require a certain timeframe. Additionally, the market sales situation after the product’s official launch is subject to multiple factors, including policy environment, market competition, and market demand, which introduces uncertainty. Investors are advised to view this matter objectively and invest rationally.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.